Sainsbury’s (SBRY) has sold Argos to newly-formed investment vehicle Swift Partners for £120 million, ending a decade of ownership of the struggling catalogue retailer. Swift Partners is led by Richard Pennycook, former
More
Legend Biotech has confirmed that chief executive Ying Huang, Ph.D., has stepped down after six years leading the company. Alan Bash, who has served as president of Carvykti since 2024, will take
More
The European Union has adopted its first substantive amendment to the AI Act, marking a significant moment in the bloc’s evolving artificial intelligence regulatory framework. Regulation (EU) 2026/1744, commonly known as the
More
The legal world’s most talked-about scandal refuses to die down, with fresh allegations emerging about senior partners at Wachtell Lipton Rosen & Katz. A viral video earlier this month showed a Wachtell
More
Investors seeking passive income have more options than ever, but choosing between cash savings and dividend stocks requires careful thought about risk and reward. Interest rates in the UK are expected to
More
SLB N.V., listed on the New York Stock Exchange under the ticker SLB, has reported its second-quarter earnings, drawing fresh scrutiny from market analysts tracking the oilfield services giant. The results have
More
Encompass Health (NYSE: EHC) has drawn renewed investor attention following a broader review of first-quarter results across outpatient and specialty care stocks. The outpatient and specialty care sector remains one of the
More
The FTSE 100 index ended the week fractionally below a significant milestone, capping off a period of robust performance for London’s premier stock market benchmark. The index came tantalisingly close to breaching
More
Manchester United’s proposed 100,000-seat stadium represents one of the largest sports infrastructure projects currently under consideration in Europe. The development is intended to become the centrepiece of a wider regeneration of the
More
Novo Nordisk has filed a lawsuit against rival Eli Lilly (LLY), accusing the US drugmaker of running “false and misleading” advertisements for its obesity drug Zepbound. The legal clash between two of
More